journal
MENU ▼
Read by QxMD icon Read
search

Advances in Therapy

journal
https://www.readbyqxmd.com/read/28210986/the-role-of-the-pharmacist-in-managing-type-2-diabetes-with-glucagon-like-peptide-1-receptor-agonists-as-add-on-therapy
#1
REVIEW
Jerry Meece
: The prevalence and associated clinical burden of type 2 diabetes (T2D) is increasing in the USA and other countries. As a consequence, the role of the pharmacist in managing T2D is expanding, and it is becoming increasingly important for pharmacists to have a complete understanding of the disease course and treatment options. Pharmacists have a key role in the use of injectable therapies, including incretin-based treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs). This article discusses the role of the pharmacist in the management of patients with T2D, particularly with respect to the use of GLP-1RAs to achieve glycemic control...
February 16, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28205056/analyzing-health-related-quality-of-life-data-to-estimate-parameters-for-cost-effectiveness-models-an-example-using-longitudinal-eq-5d-data-from-the-shift-randomized-controlled-trial
#2
Alison Griffiths, Noman Paracha, Andrew Davies, Neil Branscombe, Martin R Cowie, Mark Sculpher
INTRODUCTION: The aim of this article is to discuss methods used to analyze health-related quality of life (HRQoL) data from randomized controlled trials (RCTs) for decision analytic models. The analysis presented in this paper was used to provide HRQoL data for the ivabradine health technology assessment (HTA) submission in chronic heart failure. METHODS: We have used a large, longitudinal EuroQol five-dimension questionnaire (EQ-5D) dataset from the Systolic Heart Failure Treatment with the I f Inhibitor Ivabradine Trial (SHIFT) (clinicaltrials...
February 15, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28205055/effectiveness-of-calcifediol-in-improving-muscle-function-in-post-menopausal-women-a-prospective-cohort-study
#3
Giovanni Iolascon, Antimo Moretti, Alessandro de Sire, Dario Calafiore, Francesca Gimigliano
INTRODUCTION: The role of vitamin D supplementation on muscle function and physical performance is still debated. Calcifediol is an available treatment for hypovitaminosis D, particularly for extra-skeletal effects. Aim of this prospective cohort study was to evaluate the effectiveness of calcifediol on serum levels of 25(OH)D3, appendicular muscle strength, physical performance, and prevention of falls in post-menopausal women. METHODS: We recruited post-menopausal women aged ≥50 years, referring to an outpatient service for the management of osteoporosis over a 18-month period...
February 15, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28194578/edoxaban-in-atrial-fibrillation-and-venous-thromboembolism-ten-key-questions-and-answers-a-practical-guide
#4
REVIEW
Raffaele De Caterina, Walter Ageno, Giuseppe Boriani, Paolo Colonna, Angelo Ghirarduzzi, Giuseppe Patti, Roberta Rossini, Andrea Rubboli, Piercarla Schinco, Giancarlo Agnelli
Edoxaban is the fourth non-vitamin K antagonist oral anticoagulant now available for clinical use in the prevention of stroke/systemic embolism in atrial fibrillation (AF) and in the treatment of venous thromboembolism (VTE), after the completion of large-scale randomized comparative clinical trials with the vitamin K antagonist warfarin. Edoxaban has some peculiar pharmacological properties and outcome data. Here a group of experts in AF and VTE answers a set of questions on its practical use, trying to define the profile of patients that would be most appropriate for its use...
February 13, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28188433/the-clinical-effectiveness-of-ranibizumab-treat-and-extend-regimen-in-namd-systematic-review-and-network-meta-analysis
#5
REVIEW
Andriy Danyliv, Julie Glanville, Rachael McCool, Alberto Ferreira, Adrian Skelly, Ruth Pulikottil Jacob
INTRODUCTION: Neovascular age-related macular degeneration (nAMD) is a chronic eye condition that causes severe deterioration of vision and ultimately blindness. Two vascular endothelial growth factor inhibitors are approved for nAMD treatment in Europe: ranibizumab and aflibercept. The European license for ranibizumab was updated with an individualized "treat and extend" (T&E) regimen, which involves more proactive treatment based on changes in best corrected visual acuity (BCVA) and/or anatomical outcomes...
February 10, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28181148/erratum-to-advances-in-therapy
#6
(no author information available yet)
No abstract text is available yet for this article.
February 9, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28181147/a-clinic-based-survey-of-clinical-characteristics-and-practice-pattern-of-dry-eye-in-japan
#7
Motoko Kawashima, Masakazu Yamada, Kazuhisa Suwaki, Chika Shigeyasu, Miki Uchino, Yoshimune Hiratsuka, Norihiko Yokoi, Kazuo Tsubota
INTRODUCTION: The aim of this study was to investigate the clinical characteristics and practice pattern of patients with dry eye disease (DED) in eye clinics across Japan. METHODS: A multi-center, cross-sectional study was conducted among patients with DED who visited eye clinics in Japan. Subjective symptoms, patient's background, ocular surface features, and tear function were evaluated. Main outcome measures were tear break-up time (TBUT), Schirmer I value, kerato-conjunctival staining score, and dry eye symptom questionnaire score...
February 8, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28181146/when-people-with-opioid-induced-constipation-speak-a-patient-survey
#8
Robert S Epstein, J Russell Teagarden, Ali Cimen, Mark Sostek, Tehseen Salimi
INTRODUCTION: Opioid-induced constipation (OIC) is a common consequence of opioid use for chronic pain. OIC creates problems for patients independent of their pain syndromes, in addition to threatening pain treatment effectiveness. Healthcare practitioners need to be alert to how patients talk about OIC so that it is not missed. Using a survey mechanism, we sought patient expressions of the personal impact OIC imposes on how they are able to live their lives and on meanings that symptom relief would produce...
February 8, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28144920/the-impact-of-a-single-nucleotide-polymorphism-in-sigmar1-on-depressive-symptoms-in-major-depressive-disorder-and-bipolar-disorder
#9
Laura Mandelli, Sheng-Min Wang, Changsu Han, Soo-Jung Lee, Ashwin A Patkar, Prakash S Masand, Chi-Un Pae, Alessandro Serretti
INTRODUCTION: Ample evidence suggested a role of sigma-1 receptor in affective disorders since the interaction of numerous antidepressants with sigma receptors was discovered. A recent study on Japanese subjects found a genetic variant within the encoding gene SIGMAR1 (rs1800866A>C) associated with major depressive disorder (MDD). We aimed to evaluate the same polymorphism in both MDD and bipolar disorder (BD) as well as its relationship to response to treatment with antidepressants and mood stabilizers...
January 31, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28144919/erratum-to-chronic-obstructive-pulmonary-disease-individualized-therapy-tailored-approach-to-symptom-management
#10
Dave Singh, Marc Miravitlles, Claus Vogelmeier
No abstract text is available yet for this article.
January 31, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28144918/a-retrospective-study-of-ranibizumab-treatment-regimens-for-neovascular-age-related-macular-degeneration-namd-in-australia-and-the-united-kingdom
#11
Robert L Johnston, Hans-Joachim Carius, Adrian Skelly, Alberto Ferreira, Fran Milnes, Paul Mitchell
INTRODUCTION: Neovascular age-related macular degeneration (nAMD) is the leading cause of vision loss among persons aged 65 years and older. Anti-vascular endothelial growth factor (anti-VEGF) treatment is the recommended standard of care. The current study compares the effectiveness of ranibizumab in routine clinical practice in two countries that generally apply two different treatment regimens, treat-and-extend (T&E) in Australia or pro re nata (PRN) in the UK. METHODS: This retrospective, comparative, non-randomised cohort study is based on patients' data from electronic medical record (EMR) databases in Australia and the UK...
January 31, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28144917/impact-of-adalimumab-on-work-productivity-and-activity-impairment-in-japanese-patients-with-rheumatoid-arthritis-large-scale-prospective-single-cohort-anouveau-study
#12
Tsutomu Takeuchi, Ryo Nakajima, Shuichi Komatsu, Kiyotaka Yamazaki, Tomohiro Nakamura, Naoki Agata, Ataru Igarashi, Toshiro Tango, Yoshiya Tanaka
INTRODUCTION: The Adalimumab Non-interventional Trial for Up-verified Effects and Utility (ANOUVEAU) was a large-scale, multicenter, prospective, observational, single-cohort study that evaluated the effects of adalimumab (ADA) on rheumatoid arthritis (RA)-related work productivity and activity impairment (RA-related WPAI) and disease activity in routine rheumatology care in Japan. METHODS: Patients with RA were categorized as paid workers (PWs, ≥35 h/week), part-time workers (PTWs, <35 h/week), or homemakers (HMs, unemployed) and were administered the WPAI for RA (WPAI/RA) questionnaire...
January 31, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28138803/effectiveness-and-persistence-of-liraglutide-treatment-among-patients-with-type-2-diabetes-treated-in-primary-care-and-specialist-settings-a-subgroup-analysis-from-the-evidence-study-a-prospective-2-year-follow-up-observational-post-marketing-study
#13
Luc Martinez, Alfred Penfornis, Jean-Francois Gautier, Eveline Eschwège, Guillaume Charpentier, Amira Bouzidi, Pierre Gourdy
INTRODUCTION: The objective of this subgroup analysis is to investigate the effectiveness of liraglutide in people with type 2 diabetes (T2D) treated within the primary care physician (PCP) and specialist care settings. METHODS: EVIDENCE is a prospective, observational study of 3152 adults with T2D recently starting or about to start liraglutide treatment in France. We followed patients in the PCP and specialist settings for 2 years to evaluate the effectiveness of liraglutide in glycemic control and body weight reduction...
January 30, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28108895/chronic-wound-healing-a-review-of-current-management-and-treatments
#14
REVIEW
George Han, Roger Ceilley
Wound healing is a complex, highly regulated process that is critical in maintaining the barrier function of skin. With numerous disease processes, the cascade of events involved in wound healing can be affected, resulting in chronic, non-healing wounds that subject the patient to significant discomfort and distress while draining the medical system of an enormous amount of resources. The healing of a superficial wound requires many factors to work in concert, and wound dressings and treatments have evolved considerably to address possible barriers to wound healing, ranging from infection to hypoxia...
January 21, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28108894/behavior-modification-a-patient-and-physician-s-perspective
#15
LETTER
Elizabeth Swanson, Craig Primack
This article, co-authored by a patient affected by obesity and an obesity medicine specialist, discusses the patient's experience of living with the disease and using many different weight loss approaches until finding a lifestyle program that was appropriate for her metabolism. The physician discusses the scientific basis of insulin resistance, and why the chosen lifestyle program worked so well for this individual.
January 20, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28108893/comment-on-efficacy-and-treatment-costs-of-monotherapy-with-bdmards-in-the-treatment-of-rheumatoid-arthritis-in-patients-intolerant-to-or-inappropriate-to-continue-treatment-with-methotrexate
#16
LETTER
https://www.readbyqxmd.com/read/28083815/optimizing-the-use-of-linaclotide-in-patients-with-constipation-predominant-irritable-bowel-syndrome-an-expert-consensus-report
#17
REVIEW
Enrique Rey, Fermín Mearin, Javier Alcedo, Constanza Ciriza, Silvia Delgado-Aros, Teresa Freitas, Miguel Mascarenhas, Miguel Mínguez, Javier Santos, Jordi Serra
INTRODUCTION: Irritable bowel syndrome (IBS) is a functional bowel disorder characterized by chronic or recurrent abdominal pain in association with defecation or a change in bowel habits. A predominant disorder of bowel habits, IBS is classified into three main subtypes: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D) and IBS alternating between constipation and diarrhea (IBS-M). Linaclotide is a first-in-class, oral, once-daily guanylate cyclase-C receptor agonist (GC-CA) that is licensed for the symptomatic treatment of moderate-to-severe IBS-C in adults...
January 12, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28078541/glucagon-like-peptide-1-receptor-agonist-glp-1ra-therapy-adherence-for-patients-with-type-2-diabetes-in-a-medicare-population
#18
Hiep Nguyen, Robert Dufour, Amanda Caldwell-Tarr
INTRODUCTION: Anti-diabetes medication regimen adherence is a clinical challenge in elderly patients with type 2 diabetes (T2D) and other comorbidities associated with aging. Glucagon-like peptide-1 receptor agonists (GLP-1RA) therapies such as exenatide once weekly (QW), exenatide twice daily (BID), and liraglutide once daily (QD) are an increasingly used class of drugs with proven efficacy and tolerability. Real-world evidence on adherence to GLP-1RAs in elderly or disabled patients is limited...
January 11, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28070862/pharmacokinetic-evaluation-of-once-weekly-and-once-monthly-buprenorphine-subcutaneous-injection-depots-cam2038-versus-intravenous-and-sublingual-buprenorphine-in-healthy-volunteers-under-naltrexone-blockade-an-open-label-phase-1-study
#19
Muna Albayaty, Margareta Linden, Håkan Olsson, Markus Johnsson, Kerstin Strandgården, Fredrik Tiberg
INTRODUCTION: CAM2038 q1w (once weekly) and q4w (once monthly) are investigational buprenorphine subcutaneous (SC) formulations based on FluidCrystal(®) injection depot technology. These two drug products are being developed for opioid dependence treatment, with a target for once-weekly and once-monthly SC dosing. The rationale for developing two products with different dosing frequencies is that treatment strategies/routines, and hence different treatment preferences, can vary between patients, different stages of opioid maintenance treatment, and countries...
January 9, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28070861/efficacy-and-safety-of-vedolizumab-in-ulcerative-colitis-and-crohn-s-disease-patients-stratified-by-age
#20
Vijay Yajnik, Nabeel Khan, Marla Dubinsky, Jeffrey Axler, Alexandra James, Brihad Abhyankar, Karen Lasch
INTRODUCTION: The efficacy and safety of vedolizumab, a gut-selective α4β7 integrin antibody, were demonstrated in the GEMINI 1 and GEMINI 2 clinical trials of adults aged 18-80 years. We investigated the efficacy and safety of vedolizumab in patients stratified by age from the GEMINI trials. METHODS: Safety and efficacy, including clinical response, clinical remission, and corticosteroid-free remission, at week 6 and/or 52 were determined post hoc in patients aged <35, 35 to <55, and ≥55 years...
January 9, 2017: Advances in Therapy
journal
journal
29381
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"